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Background. We have recently demonstrated an increase in
apoptosis in Han:SPRD rat kidneys with autosomal-dominant
polycystic kidney disease (ADPKD). Caspase-3 and caspase-7
are major mediators of apoptosis. There are two pathways of
caspase-3 and caspase-7–mediated apoptosis: (1) the “extrin-
sic” pathway involving the death receptor Fas, Fas ligand (FasL),
and caspase-8 and (2) the “mitochondrial” or “intrinsic” path-
way involving Bcl-2 proteins, caspase-2, cytochrome c release,
and caspase-9. The aim of the present study was to investigate
the pathways of apoptosis in 3-week-old Han:SPRD rats with
ADPKD.
Methods. Fluorescent substrates were used to measure cas-
pase activity. mRNA and protein was determined by ribonu-
clease protection assays and immunoblotting, respectively. The
effect of caspase inhibitors on caspase activity in polycystic kid-
neys was determined.
Results. Caspase-3 and caspase-7 activity was more than
100% increased in homozygous (Cy/Cy) compared to heterozy-
gous (Cy/+) and normal littermate control (+/+) kidneys. Ri-
bonuclease protection assays demonstrated no difference in
caspase-3 mRNA. On immunoblotting, there was an increase
in the proform of caspase-3 and caspase-7 in Cy/Cy compared
to +/+ and Cy/+ kidneys. Caspase-8 and caspase-9 activity was
more than 100% increased in Cy/Cy compared to Cy/+ and +/+
kidneys. On immunoblotting, there was an increase of the pro-
form of both caspase-8 and caspase-9 in Cy/Cy kidneys. There
was also an increase in cytochrome c release into the cytosol
and an increase in caspase-2 protein and activity in Cy/Cy kid-
neys. On ribonuclease protection assay there was no difference
in FasL mRNA between +/+, Cy/+, and Cy/Cy kidneys. Short-
term treatment of Cy/Cy rats with the caspase inhibitor IDN-
8050 resulted in inhibition of caspase-3 and caspase-7 activity
in the kidney.
Conclusion. In Cy/Cy kidneys with ADPKD, there was an
increase of the proform of caspase-9, an increase in cytochrome
c release into the cytosol, and an increase in caspase-2 protein
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and activity demonstrating involvement of the intrinsic path-
way. There was an increase in the proform of caspase-8 demon-
strating involvement of the extrinsic pathway. No differences in
FasL mRNA were seen suggesting that the extrinsic pathway is
independent of the death receptor ligand, FasL.
Apoptosis is a pathologic feature of polycystic kidney
disease (PKD) [1]. Increased levels of apoptosis are ob-
served in human autosomal-dominant PKD (ADPKD)
[1–4] and dysplastic renal disease [5]. Increased apop-
tosis is also a feature of animal models of PKD, in-
cluding the cpk mouse model of autosomal-recessive
PKD (ARPKD) [3], transgenic mice overexpressing the
proto-oncogene c-myc (SBM mice) [6], mice lacking
the transcription factor activating protein 2b (AP-2b)
[7], Bcl-2–deficient mice [8], and the Han:SPRD rat
[9]. Apoptosis was detected in kidneys of humans with
ADPKD regardless of renal function, but not in normal
kidneys [3]. Mutations of PKD1 are responsible for ap-
proximately 85% of cases of ADPKD. A recent study sug-
gests that polycystin-1, the gene product of PKD1, may
regulate apoptosis during spontaneous tubulogenesis in
Madin-Darby canine kidney (MDCK) cells [10].
Both caspase-3 and caspase-7 play a crucial and ex-
tensively studied role in the promotion of all forms of
apoptotic cell death [11]. There are two major pathways
of caspase-mediated apoptosis [12] (Fig. 1). In the mito-
chondrial or “intrinsic” pathway, stress-induced signals
act via Bcl-2 proteins to cause cytochrome c release
from mitochondria. Caspase-2 is a recently discovered
caspase that is also a critical initiator of the mitochon-
drial apoptosis pathway [13]. Cytochrome c binds to the
cytosolic protein, apoptosis protease-activating factor-1
(APAF-1), which recruits and activates caspase-9. Active
caspase-9 in turn recruits and activates the “execution-
ers” procaspase-3 and procaspase-7. In the “extrinsic”
pathway, the binding of a ligand to its death receptor
recruits an adaptor protein that in turn recruits and
activates procaspase-8. For example, Fas ligand (FasL)
binds to its death receptor Fas that recruits an adaptor
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Fig. 1. Major pathways of caspase-3–mediated apoptosis. In the mito-
chondrial pathway, the balance of pro- and antiapoptotic Bcl-2 family
proteins as well as caspase-2 determines cytochrome c release from
mitochondria. Cytochrome c binds to the cytosolic protein, apopto-
sis protease-activating factor-1 (APAF-1), which recruits caspase-9.
Caspase-9 in turn activates the “executioner” procaspase-3. In the death
receptor pathway, the binding of a ligand (e.g. Fas ligand) to its death
receptor recruits an adaptor protein that in turn recruits procaspase-8.
protein called Fas-associated death domain (FADD).
FADD in turn recruits and activates procaspase-8. We
have recently demonstrated a decrease in the antiapop-
totic Bcl-XL protein and an increase in caspase activity
and apoptosis in 2-week-old Han:SPRD rat kidneys with
ADPKD [9].
The molecular pathways of caspase-mediated apop-
tosis, however, have not been characterized in the
Han:SPRD rat. The Han:SPRD rat closely resembles
ADPKD and therefore is a worthy model to study the
molecular pathways of apoptosis. In the present study,
therefore, the extrinsic and intrinsic pathways of caspase-
mediated apoptosis were investigated.
METHODS
Animals
The study was conducted in 3-week-old normal
(+/+), heterozygous (Cy/+), and homozygous (Cy/Cy)
Han:SPRD rats. The Cy/Cy Han:SPRD rats died at
4 weeks of age from massive polycystic kidneys and re-
nal failure [14]. All the normal rats and Cy/+ rats studied
were males. The Cy/Cy rats studied were both male and
female. A colony of Han:SPRD rats was established in
our animal care facility from a litter that was obtained
from the Polycystic Kidney Program at the University of
Kansas Medical Center, Kansas City, Kansas. The study
protocol was approved by the University of Colorado
Health Sciences Center Animal Care and Use Commit-
tee. Rats had free access to tap water and standard rat
chow.
Tissue preparation
Rats were anesthetized by intraperitoneal injection of
pentobarbital sodium (50 mg/kg body weight) and kid-
neys were removed. The kidneys were weighed after re-
moval. The left kidney was fixed in 4% paraformaldehyde
in phosphate-buffered saline (PBS) for 120 minutes and
then put into 70% ethanol for histologic examinations.
The right kidney was frozen in liquid nitrogen and stored
at –80◦C for ribonuclease protection assays, caspase as-
says, and Western blot analyses.
Blood was drawn by cardiac puncture. Serum cre-
atinine was measured using a Beckman autoanalyzer
(Beckman Instruments, Fullerton, CA, USA).
Morphologic analysis of cystic disease
Tissues were fixed in 4% paraformaldehyde. Four mi-
crometer transverse sections were stained with hema-
toxylin and eosin and periodic acid-Schiff (PAS).
Measurements were be made in renal cortex in the Cy/+
rats because the cystic disease mainly involves the cortex
[14]. Cyst volume density was scored in histologic sec-
tions projected onto a standard grid using point counting
stereology as previously described [15]. Briefly, the pres-
ence of cysts at the crossing points on a 10 × 10 division
grid were determined. One hundred points in 5 to 10 high
power fields of each section were be counted in areas of
the cortex at 90, 180, and 270 degrees from the hilum to
guard against reviewer bias and field selection variation.
Tissue preparation of cytosolic fraction for cytochrome c
immunoblot analysis
The cytochrome c release assay was performed as pre-
viously described [16]. Kidneys were rapidly removed
from the rats. Half a kidney was immediately ho-
mogenized in 1.5 mL of mitochondrial buffer A us-
ing 10 strokes of a glass Dounce homogenizer. Buffer
A contained 250 mmol/L sucrose, 20 mmol/L HEPES-
potassium hydroxide (KOH) (pH 7.4), 10 mmol/L
KCl, 1.5 mmol/L sodium ethyleneglycoltetraacetic
acid (Na EGTA), 1.5 mmol/L sodium ethylenedi-
aminetetraacetic acid (Na EDTA), 1 mm MgCl2,
1 mmol/L dithiothreitol (DTT) plus proteinase inhibitors:
1 mmol/L 4-(2-aminoethyl)benzenesulfonyl fluoride
(AEBSF), 15 lmol/L pepstatin A, 14 lmol/L L-trans-
epoxysuccinyl-leucylamide-(4-guanido)-butane (E-64),
40 lmol/L bestatin, 22 lmol/L leupeptin, and 0.8 lmol/L
aprotonin. The homogenate was centrifuged at 1000g for
10 minutes at 4◦C to remove large debris, nuclei, and un-
broken cells. Supernatants containing mitochondria were
further centrifuged at 40,000g for 20 minutes at 4◦C. The
resulting supernatant was saved as the cytosolic extract.
Caspase assays
The activity of caspases in was determined by
use of flourescent substrates as we have previously
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described [17] with modifications [18]. Cytosolic extracts
were prepared as follows. Renal cortex was mixed with a
lysis buffer containing 25 mmol/L Na+ Hepes, 2 mmol/L
DTT, 1 mM EDTA, 0.1% 3-[(3-cholamidopropyl)
dimethylammonio]-1-pro-panesulfonate (CHAPS), 10%
sucrose, 1 mmol/L phenylmethylsulfonyl fluoride
(PMSF), and 1 lmol/L pepstatin A, pH 7.2, and homog-
enized with 10 strokes in a glass-Teflon homogenizer.
The lysate was then centrifuged at 4◦C at 100,000g in a
Beckman Ti70 rotor for 1 hour (Beckman Instruments).
The resultant supernatants (cytosolic extracts) were
immediately frozen in liquid nitrogen (N2) and stored
at −70◦C until use. Lysate protein was measured by the
Bio-Rad DC Protein Assay Kit (Bio-Rad, Hercules, CA,
USA) with bovine serum albumin (BSA) as standards.
The caspase assay was then performed on this super-
natant as follows: 200 lg protein (20 to 50 lL volume)
was added to 10 lL of the substrate (final concentra-
tion 50 lmol/L). The volume was made up to 200 lL
with the caspase assay buffer. The assay buffer for
caspase-3 and caspase-7 contained 250 mmol/L K+
Hepes, 50 mmol/L KCl, 1 mmol/L DTT, 1 mmol/L EDTA,
and 0.1% CHAPS, pH 7.4. Ac-Asp-Glu-Val-Asp-7
-amido-4-methyl coumarin (Ac-DEVD-AMC) in 10%
dimethyl sulfoxide (DMSO) was used as a susceptible
substrate for caspase-3 and caspase-7 [19]. The assay
buffer for caspase-8 and caspase-9 contained 75 mmol/L
Na+ 3-[N-morpholino]propane sulfonic acid (MOPS),
10% glycerol, 1 mmol/L DTT, 1 mmol/L EDTA, pH
7.4. Ac-Ile-Glu-Pro-Asp-7-Amino-4-methylcoumarin
(IEPD-AMC) in 10% DMSO was used as a susceptible
substrate for caspase-8 and caspase-9 [19]. The assay
buffer for caspase-2 contained 50 mmol/L Hepes,
100 mmol/L NaCl, 10 mmol/L DTT, 1 mmol/L EDTA,
0.1% CHAPS, and 10% glycerol, pH 7.4. Z-Val-Asp-
Val-Ala-Asp-AMC (Z-VDVAD-AMC) was used as a
susceptible substrate for caspase-2. The assay buffer for
caspase-1 contained 100 mmol/L Hepes, 10% sucrose,
10 mmol/L DTT, 0.1 mmol/L EDTA, and 0.1% CHAPS,
pH 7.5. Ac-Tyr-Val-Ala-Asp-AMC (Ac-YVAD-AMC)
was used as a susceptible substrate for caspase-1. The
solution was preincubated for 10 minutes at 30◦C before
substrate was added. The reaction was then initiated by
addition of substrate. Peptide cleavage was measured
over 1 hour at 30◦C using a Cytofluor 4000 series fluores-
cent plate reader (Perseptive Biosystems, Framingham,
MA, USA) at an excitation wavelength of 380 nm and
an emission wavelength of 460 nm. An AMC standard
curve was determined for each experiment. Caspase
activity was expressed in nmol AMC released per minute
of incubation time per mg of lysate protein.
Caspase activity was also measured in nuclear extracts.
Nuclei were isolated by the method of Chauveau, Moule,
and Rouiller [20] with modifications [21]. The entire pro-
cedure was performed at 4◦C. Briefly a whole kidney was
minced with a blade and then homogenized in a Dounce
homogenizer with a loose fitting pestle in a buffer con-
taining 0.33 mol/L sucrose and 0.004 mol/L CaCl2. The
homogenate was filtered through a layer of cheesecloth
and centrifuged at 600 × g for 10 minutes. The resulting
pellet was homogenized in a Dounce homogenizer with
a tight fitting pestle in a buffer containing 0.25 mol/L su-
crose and 0.003 mol/L CaCl2, underlaid with an equal
volume of 0.34 mol/L sucrose and 0.003 mol/L CaCl2
and then centrifuged at 1500g for 15 minutes. The pellet
was resuspended in 9 volumes of 2.4 mol/L sucrose and
0.003 mol/L CaCl2 by homogenization. The homogenate
was then centrifuged at 45,000g in a Beckman Ti70 rotor
for 1 hour (Beckman Instruments). The pellet was re-
suspended in 0.25 mol/L sucrose and 0.003 mol/L CaCl2
and centrifuged at 600g for 10 minutes. The presence of
nuclei in the pellet was confirmed by microscopy demon-
strating only rounded nuclei with clear sharp nucleoli and
no other particles. The nuclei were resuspended in lysis
buffer and the caspase assay was performed as described
above.
Immunoblot analysis
Caspase-8 and caspase-9 belong to group III or “ini-
tiator” caspases that share the same synthetic substrate
specificities [19]. Caspase-3 and caspase-7 belong to
group II or “executioner” caspases and also share the
same synthetic substrate specificities [19]. The substrates
used in fluorescence or colorimetric assays preferentially
detect active members of a given caspase group rather
than a specific caspases [22]. Thus, immunoblot analysis
for specific caspases was undertaken.
Immunoblot analysis was performed as we have pre-
viously described [17]. Renal cortex was homogenized
in lysis buffer (in mmol/L): 5 Na2HPO4, 5 NaH2PO4,
150 NaCl, 1 EDTA, 0.1% Triton X-100, 50 NaF, and
0.2 Na3VO4, and 0.1% b-mercaptoethanol, pH 7.2, plus
proteinase inhibitors 1 mmol/L AEBSF, 15 lmol/L pep-
statin A, 14 lmol/L E-64, 40 lmol/L bestatin, 22 lmol/L
leupeptin, and 0.8 lmol/L aprotonin. The homogenates
were centrifuged (14,000 rpm at 4◦C for 10 minutes) to
remove unbroken cells and debris. Supernatants were
mixed with sample buffer containing 50 mmol/L Tris
base (pH 6.8), 0.5% glycerol, 0.01% bromphenol blue,
and 0.75% sodium dodecyl sulfate (SDS) and heated
at 95◦C for 5 minutes. Equal amounts of protein (50 to
100 lg/lane) were fractionated by Tris-glycine-SDS-7.5 or
12.5% polyacrylamide gel electrophoresis (PAGE). The
electrophoretically separated proteins were then trans-
ferred to an Immobilon P membrane (Millipore, Bed-
ford, MA, USA) by wet electroblotting for 90 minutes.
The membranes were blocked with 5% nonfat dry milk in
TBST [50 mmol/L Tris (pH 7.5), 150 mmol/L NaCl, and
0.1% Tween-20] buffer at pH 7.5 for 1 hour at room tem-
perature. Immunoblot analyses were performed with the
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following primary antibodies: (1) a rabbit polyclonal anti-
body raised against a recombinant protein corresponding
to amino acids 1-277 representing the full length precur-
sor form of caspase-3 of human origin (1:200) (catalogue
number sc-7148) (Santa Cruz Biotechnology, Inc., Santa
Cruz, CA, USA) [a purified recombinant caspase-3 (Up-
state Group Inc, Lake Placid, NY, USA) was used as a
positive control]; (2) a rabbit polyclonal antibody that
detects the full-length protein of caspase-7 (1:500) (Cell
Signaling Technology, Inc., Beverly, MA, USA) [Jurkat
whole cell lysate (catalogue number sc-2204) (Santa Cruz
Biotechnology, Inc) was used a positive control]; (3) a rab-
bit anticaspase-8 polyclonal antibody that detects the full-
length recombinant human caspase-8 protein (1:2000)
(catalogue number AAP-118) (StressGen Biotechnolo-
gies Corp, Victoria, BC, Canada) (the immunogen for the
antibody was full-length recombinant human caspase-8
protein and the antibody has species reactivity to human,
mouse, and rat); (4) a mouse anticaspase-9 monoclonal
antibody that detects the human caspase-9 glutathione-S-
transferase (GST) fusion protein fragment correspond-
ing to the N-terminal region, residues 1-250 (1:2000)
(catalogue number AAM-139) (StressGen Biotechnolo-
gies Corp.); (5) purified mouse anticytochrome c mono-
clonal antibody (1:1000) (catalog number 556433) (BD
Pharmingen, San Diego, CA, USA) (RSV-3T3 cell lysate
was used as a positive control); and (6) a rabbit polyclonal
antibody raised against a peptide mapping at the amino
terminus of caspase-2 of human origin (1:1000) (cata-
logue number sc-623) (Santa Cruz Biotechnology, Inc.)
(the antibody has species reactivity to human, mouse,
and rat) [Jurkat whole cell lysate (catalogue number sc-
2204) (Santa Cruz Biotechnology, Inc.) was used a posi-
tive control]. The membranes were incubated overnight
at 4◦C with primary antibodies, washed in TBST buffer
and further incubated with sheep antimouse IgG or don-
key antirabbit IgG coupled to horseradish peroxidase
(Amersham, Piscataway, NJ, USA) at 1:1000 dilution
in TBST buffer for 1 hour at room temperature. Sub-
sequent detection was carried out by enhanced chemi-
luminescence (ECL) (Amersham), according to the
manufacturer’s instructions. Prestained protein markers
(Bio-Rad) were used for molecular mass determination.
Ribonuclease protection assay
FasL, caspase-2, caspase-3, Bax, and Bcl-XL mRNA
levels were analyzed by RNAse protection assays us-
ing rAPO-1 multiprobe template (BD Pharmingen).
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
was included as an internal control. Total RNA was
prepared form whole kidney using the TRIzol method.
mRNA was enriched using a MicroPoly(A)Pure Kit
(Ambion, Inc., Austin, TX, USA). Nonradioactive RNA
probes were transcribed from a multiprobe template
set for rat apoptosis factors (rAPO-1) (Pharmingen).
An in vitro RNA transcription kit (MAXIscript T7)
(Ambion, Inc.) was applied with the addition of biotin-
16-uridine triphosphate (UTP) for labeling the probes.
Five micrograms of mRNA enriched samples were incu-
bated with about 600 pg of the probe overnight at 56◦C,
and then digested with RNase. Protected mRNAs were
analyzed by electrophoresis on a 5% denaturing poly-
acrylamide gel and transferred to a positively charged
nylon membrane. Chemiluminescence was generated
with streptavidin-conjugated alkaline phosphatase. The
membrane was then exposed to a film.
Immunohistochemistry
Immunohistochemical localization of active caspase-3
was performed on paraformaldehyde-fixed and paraffin-
embedded tissues. Paraffin blocks were sectioned at 4 lm
thickness on slides. Paraffin sections were deparaffinized
in xylene and rehydrated in graded ethanols. The sections
were then heated to 110◦C in 1 mmol/L EDTA in PBS in
a cooker (Decloaking Chamber) (Biocare Medical, Wal-
nut Creek, CA, USA) for 10 minutes for antigen retrieval.
Sections were incubated with blocking buffer (5% normal
goat serum and 2% BSA in PBS) for 30 minutes to block
nonspecific binding. Sections were then incubated with
antiactive caspase-3 antibody (Promega, Madison, WI,
USA) (catalogue number G7481) 1:50 in blocking buffer
for 1 hour. Negative control sections were incubated with
blocking buffer. Following wash with TBST (10 mmol/L
Tris/HCl, pH 7.5, 150 mmol/L NaCl, and 0.1% Tween-
20), the sections were incubated with horseradish perox-
idase (HRP)-labeled polymer (Dako EnVision System,
Carpinteria, CA, USA) (catalogue number K1395) for
1 hour. Sections were washed with TBST again and the
antigen site was visualized by incubating the sections with
the substrate 3,3′-diaminobenzidine (DAB) chromogen.
Negative control sections showed no staining with DAB.
Caspase inhibition
The pan caspase inhibitor IDN-8050 was obtained from
Idun Pharmaceuticals, Inc. (San Diego, CA, USA). The
inhibitor (1 mg) or vehicle [polyethylene glycol 300 (PEG
300)] was administered intraperitoneally. Three hours
later, both kidneys were removed, washed with normal
saline, frozen in liquid nitrogen, and stored at −80◦C for
caspase assays.
The caspase-2 inhibitor, Z-Val-Asp(OMe)-Val-Ala-
Asp(OMe)-fluoromethylketone (Z-VDVAD-FMK) was
obtained from Enzyme Systems Products (Livermore,
CA, USA). Cy/Cy rats were injected intraperitoneally
with the inhibitor at a dose of 20 mg/kg as recommended
by the manufacturer. Three hours later, both kidneys
were removed, washed with normal saline, frozen in liq-
uid nitrogen, and stored at –80◦C for caspase assays.
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Statistical analysis
Nonnormally distributed data were analyzed by the
nonparametric unpaired Mann-Whitney test. Multiple
group comparisons were performed using a one-way
analysis of variance (ANOVA) with post test according
to Newman-Keuls. A P value of <0.05 was considered
statistically significant. Values are expressed as means ±
SE.
RESULTS
Cyst formation and renal function
In 3-week-old rats, cyst volume density (%) was 0.5 ±
0.1 in +/+ and 7.4 ± 1.4 in Cy/+ (P < 0.05 vs. +/+) and
76.8 ± 3.2 in Cy/Cy (P < 0.001 vs. Cy/+) (N = 6). Serum
creatinine (mg/dL) was 0.4 ± 0.02 in +/+ and 0.4 ± 0.03
in Cy/+ (P = NS vs. +/+) and 1.1 ± 0.07 in Cy/Cy (P <
0.001 vs. Cy/+) (N = 6).
In 8-week-old rats, cyst volume density (%) was 0.6 ±
0.2 in +/+ and 34 ± 6 in Cy/+ (P < 0.0001 vs. +/+) (N =
7). Serum creatinine (mg/dL) was 0.4 ± 0.02 in +/+ and
0.3 ± 0.02 in Cy/+ (P = NS vs. +/+) (N = 7).
Caspase-3 and caspase-7 activity
Caspase-3 and caspase-7 activity was measured using
the fluorescent substrate DEVD-AMC. Caspase-3 and
caspase-7 activity (nmol/min/mg) was 8.8 ± 1.2 in +/+
and 8.5 ± 0.8 in Cy/+ (P = NS vs. +/+) (N = 11) and
16.7 ± 1.8 in Cy/Cy rats (P < 0.01 vs. +/+ and Cy/+)
(N = 7) (Fig. 2). We previously demonstrated a slight
increase in caspase-3 activity in 2-week-old Cy/+ kidneys
compared to +/+ [9]. This increase was not reproducible
in the present study in 3-week-old kidneys. As caspase-3
and caspase-7 activity was not increased in Cy/+ rats at
3 weeks, it was determined whether it increased at a later
age. Caspase-3 activity was increased in 8-week-old Cy/+
rat kidneys. Caspase-3 activity (nmol/min/mg) in 8-week-
old rats was 10 ± 1 in +/+ and 14 ± 1 in Cy/+ (P = 0.02)
(N = 7).
Caspase-3 and caspase-7 activity was also measured
in isolated nuclei. Caspase-3 and caspase-7 activity
(nmol/min/mg), was 3.5 ± 0.4 in nuclei isolated from +/+
rat kidneys and 4.8 ± 0.4 in Cy/+ (P = NS vs. +/+) (N =
11) and 6.6 ± 0.9 in Cy/Cy rats (P < 0.05 vs. +/+) (NS vs.
Cy+, N = 4).
Caspase-3 mRNA
Ribonuclease protection assay for caspase-3, demon-
strated no difference in caspase-3 mRNA between Cy/Cy,
Cy/+ and normal littermate controls (+/+) (Fig. 3).
Caspase-3 and caspase-7 protein
On immunoblot for caspase-3, there was an increase
in the proform (32 kD) in Cy/Cy compared to +/+ and
Cy/+ rat kidneys (Fig. 4). On immunoblot for caspase-7,
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Fig. 2. Caspase-3 and caspase-7 activity in 3-week-old Han:SPRD rat
kidneys. Cytosolic extracts of renal cortex were prepared. The activity
of caspase-3 and caspase-7 was determined using the fluorescent sub-
strate Ac-Asp-Glu-Val-Asp-7-amido-4-methyl coumarin (Ac-DEVD-
AMC). There was an increase in caspase-3 and caspase-7 activity in
3-week-old homozygous (Cy/Cy) compared to normal littermate con-
trols (+/+) and heterozygous (Cy/+) rat kidneys. ∗P < 0.01 vs. +/+ and
Cy/+ (N = 11).
there was an increase in the proform (35 kD) in Cy/Cy
compared to +/+ and Cy/+ rat kidneys (Fig. 5). Caspase-
7 was not detected in +/+ and Cy/+ kidneys (Fig. 5).
Caspase-8 and caspase-9 activity
Caspase-8 and caspase-9 activity was measured us-
ing the fluorescent substrate IEPD-AMC. Caspase-8 and
caspase-9 activity (nmol/min/mg) was 60 ± 10 in +/+ and
72 ± 10 in Cy/+ (P = NS vs. +/+) and 123 ± 7 in Cy/Cy
rats (P < 0.001 vs. +/+ and Cy/+) (N = 10) (Fig. 6).
As caspase-8 and caspase-9 activity was not increased in
Cy/+ rats at 3 weeks, it was determined whether it in-
creased at a later age. Caspase-8 and caspase-9 activity
was increased in 8-week-old Cy/+ rats. Caspase-8 and
caspase-9 activity (nmol/min/mg) in 8-week-old rats was
18 ± 2 in +/+ and 25 ± 0.5 in Cy/+ (P < 0.05 vs. +/+)
(N = 4).
Caspase-8 and caspase-9 protein
As IEPD-AMC does not differentiate between
caspase-8 and caspase-9, immunoblot analysis was un-
dertaken. There was a massive increase in the pro-form
of caspase-8 (55 kD) in Cy/Cy vs. +/+ and Cy/+ kidneys
(Fig. 7). In Cy/Cy kidneys there was an increase in the
proform (46 kD) of caspase-9 (Fig. 8).
Mitochondrial release of cytochrome c
Release of cytochrome c from mitochondria is an es-
sential factor in the activation of caspase-9 [23]. An in-
crease in cytochrome c (15 kD) in the cytosol was detected
on immunoblot analysis in Cy/Cy compared to +/+ and
Cy/+ kidneys (Fig. 9).
Caspase-2
It has recently been demonstrated that caspase-2 is
essential for the permeabilization of mitochondria and
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Fig. 3. Ribonuclease protection assay and densitometic analysis. (A)
Ribonuclease protection assay showed no consistent differences in Bcl-
XL, FasL, caspase-3, caspase-2, and Bax mRNA between 3-week-old
homozygous (Cy/Cy), heterozygous (Cy/+), and normal littermate con-
trols (+/+). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
was included as an internal control. (B) Densitometric analysis of the
protected mRNA bands in three separate experiments from three dif-
ferent litters was performed using the computer program Scion Im-
age for Windows that is available on the National Institutes of Health
(NIH) website. Results were expressed as the ratio of the band density
to GAPDH. No statistical differences in the band density of Bcl-XL,
FasL, caspase-3, caspase-2, and Bax mRNA relative to GAPDH were
seen between homozygous (Cy/Cy), heterozygous (Cy/+), and normal
littermate controls (+/+). NS is not significant.
32
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Fig. 4. Immunoblot analysis for caspase-3 in 3-week-old Han:SPRD
rat kidneys. On immunoblot for caspase-3, there was an increase of
the proform (32 kD) in homozygous (Cy/Cy) compared to normal
littermate controls (+/+) and heterozygous (Cy/+) rat kidneys. Pos-
itive control (Pos) is purified recombinant caspase-3. Representative
immunoblot of three separate experiments from three separate litters.
35
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Fig. 5. Immunoblot analysis for caspase-7 in 3-week-old Han:SPRD
rat kidneys. As the fluorescent substrate, Ac-Asp-Glu-Val-Asp-7-
amido-4-methyl coumarin (DEVD-AMC) (Fig. 2) does not differenti-
ate between caspase-3 and caspase-7 activity, immunoblot analysis was
undertaken. There was a massive increase in the proform (35 kD) of
caspase-7 in homozygous (Cy/Cy) vs. normal littermate controls (+/+)
and heterozygous (Cy/+) kidneys. Caspase-7 was not seen in +/+ and
Cy/+ kidneys. Jurkat whole cell lysate was used a positive control (Pos).
Representative immunoblot of three separate experiments from three
separate litters.
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Fig. 6. Caspase-8 and caspase-9 activity in 3-week-old Han:SPRD
rat kidneys. Cytosolic extracts of renal cortex were prepared. The
activity of caspase-8 and caspase-9 was determined using the flu-
orescent substrate Ac-Ile-Glu-Pro-Asp-7-Amino-4-methylcoumarin
(IEPD-AMC). There was an increase in caspase-8 and caspase-9 ac-
tivity in homozygous (Cy/Cy) compared to normal littermate controls
(+/+) and heterozygous (Cy/+) rat kidneys. ∗P < 0.001 vs. +/+ and
Cy/+ (N = 10).
release of cytochrome c [13]. Caspase-2 has two mes-
senger RNAs generated by alternative splicing, which
encode caspase-2L and caspase-2S. Although caspase-
2L induces apoptosis, caspase-2S has the ability to an-
tagonize cell death [24, 25]. There was no change is
caspase-2L mRNA between +/+, Cy/+, and Cy/Cy kid-
neys (Fig. 3). Caspase-2 activity was increased in Cy/Cy
kidneys (Fig. 10). Caspase-2 activity (nmol/min/mg) was 0
in +/+ and 1.75 ± 1.1 in Cy/+ (P = NS vs. +/+) and 5.3 ±
1.2 in Cy/Cy rats (P < 0.05 vs. +/+) (N = 3 in +/+, N = 3
in Cy/+, and N = 6 in Cy/Cy) (Fig. 10). Caspase-2 activ-
ity was not increased in 8-week-old Cy/+ rats. Caspase-2
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Fig. 7. Immunoblot analysis for caspase-8 in 3-week-old Han:SPRD
rat kidneys. As the fluorescent substrate, Ac-Ile-Glu-Pro-Asp-7-
Amino-4-methylcoumarin (IEPD-AMC) (Fig. 6) does not differenti-
ate between caspase-8 and caspase-9 activity, immunoblot analysis was
undertaken. There was a massive increase in the proform (55 kD) of
caspase-8 in homozygous (Cy/Cy) compared to normal littermate con-
trols (+/+) and heterozygous (Cy/+) rat kidneys.
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Fig. 8. Immunoblot analysis for caspase-9 in 3-week-old Han:SPRD
rat kidneys. As the fluorescent substrate, Ac-Ile-Glu-Pro-Asp-7-
Amino-4-methylcoumarin (IEPD-AMC) (Fig. 6) does not differentiate
between caspase-8 and caspase-9 activity, immunoblot analysis was un-
dertaken. There was an increase in the proform (46 kD) of caspase-9
in homozygous (Cy/Cy) compared to normal littermate controls (+/+)
and heterozygous (Cy/+) rat kidneys. Jurkat whole cell lysate was used
a positive control (Pos).
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Fig. 9. Immunoblot analysis for cytochrome c in 3-week-old
Han:SPRD rat kidneys. Kidneys were rapidly removed from the rats
and immediately homogenized. Preparation of cytosolic extracts with-
out disrupting the mitochondria is outlined in the Methods section. An
increase in cytochrome c (15 kD) in the cytosol was detected on im-
munoblot analysis in homozygous (Cy/Cy) compared to normal litter-
mate controls (+/+) and heterozygous (Cy/+) kidneys. Representative
immunoblot of at least three separate experiments from three separate
litters.
activity (nmol/min/mg) in 8 week old rats was 1.9 ± 0.4
in +/+ and 1.3 ± 0.5 in Cy/+ (P = NS vs. +/+) (N =
4). On immunoblot for caspase-2, there was an increase
in the proform (45 kD) in Cy/Cy compared to +/+ and
Cy/+ rat kidneys (Fig. 11).Caspase-2L mRNA encodes a
protein product of 435 amino acids that is homologous
to the P20 and P10 subunits of caspase-1 (27% identity)
[24]. We also measured caspase-1 activity. Caspase-1 is
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Fig. 10. Caspase-2 activity in 3-week-old Han:SPRD rat kidneys. Cy-
tosolic extracts of renal cortex were prepared. The activity of caspase-
2 was determined using the fluorescent substrate Z-Val-Asp-Val-Ala-
Asp-Amino-4-methylcoumarin (Z-VDVAD-AMC). There was an in-
crease in caspase-2 activity in homozygous (Cy/Cy) compared to nor-
mal littermate controls (+/+) and heterozygous (Cy/+) rat kidneys. ∗P
< 0.05 vs. +/+ and Cy/+, in +/+ (N = 3), in Cy/+ (N = 3), and in Cy/Cy
(N = 6).
Cy/CyPos Cy/++/+
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Fig. 11. Immunoblot analysis for caspase-2 in 3-week-old Han:SPRD
rat kidneys. On immunoblot for caspase-2, there was an increase of the
pro-form (45 kD) in homozygous (Cy/Cy) compared to normal litter-
mate controls (+/+) and heterozygous (Cy/+) rat kidneys. Jurkat whole
cell lysate was used a positive control (Pos). Representative immunoblot
of five separate experiments from five separate litters.
a proinflammatory caspase that activates the cytokines
interleukin (IL)-1 and IL-18. Caspase-1 activity was no
different in +/+, Cy/+, and Cy/Cy kidneys. Caspase-1 ac-
tivity (nmol/min/mg) was 337 ± 69 in +/+ and 377 ± 76
in Cy/+ (P = NS vs. +/+) (N = 5) and 304 ± 51 in Cy/Cy
rats (P = NS vs. +/+ and Cy/+) (N = 5).
Fas ligand mRNA
Renal tubular epithelial cells are known to express Fas
ligand (FasL) [26]. In the “extrinsic” pathway of apopto-
sis, the binding of FasL to the death receptor Fas is one
of the triggers that leads to the recruitment of caspase-
8 and apoptosis [27]. On ribonuclease protection assay
there was no difference in FasL mRNA between +/+,
Cy/+, and Cy/Cy kidneys (Fig. 3).
Immunohistochemistry for active caspase-3
Kidney sections were stained with an antibody that
specifically detects the active form of caspase-3. No stain-
ing was detected in +/+ and Cy/+ kidneys (Fig. 12A
and B). In Cy/Cy kidneys, staining was detected in
tubular cells lining cysts (Fig. 12C) and in the interstitium
(Fig. 12D)
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Fig. 12. Immunohistochemistry. Sections were incubated with an antiactive caspase-3 antibody from Promega Corporation (1:50). The antigen
site was visualized by incubating the sections with the substrate 3,3′-diaminobenzidine (DAB) chromogen (brown color). No staining was detected
in +/+ and Cy/+ kidneys (A and B). In Cy/Cy kidneys, staining (brown color) (arrows) was detected in tubular cells lining cysts (C) and in the
interstitium (D). No staining was detected in glomeruli in +/+, Cy/+, and Cy/Cy kidneys. Negative control sections showed no staining with DAB.
Cysts are marked with an asterisk (∗).
Caspase inhibition
The pan caspase inhibitor IDN-8050 (1 mg) or vehicle
(PEG 300) was administered intraperitoneally. Caspase-3
and caspase-7 activity was measured in the Cy/Cy kid-
neys 3 hours after the administration of the inhibitor.
Caspase activity in the kidney was 30.5 ± 6.3 in vehicle-
treated rats and 4.5 ± 1.5 in IDN-8050–treated rats (P <
0.05 vs. vehicle-treated) (N = 3) (Fig. 13). Thus intraperi-
toneal administration of the caspase inhibitor IDN-8050
in the short-term virtually completely inhibits caspase-3
and caspase-7 activity in Cy/Cy kidneys.
The caspase-2 inhibitor Z-VDVAD-FMK was adminis-
tered intraperitoneally. Caspase-2 activity was measured
in the Cy/Cy kidneys 3 hours after the administration of
the inhibitor. Caspase-2 activity in the kidney was 5.3 ±
1.2 in untreated rats and 7.5 ± 2.7 in Z-VDVAD-FMK–
treated rats (P = NS vs. untreated) (N = 6). Thus in-
traperitoneal administration of the specific caspase-2 in-
hibitor Z-VDVAD-FMK in the short-term had no effect
on caspase-2 activity in Cy/Cy kidneys.
DISCUSSION
In 1989, Kaspareit-Rittinghausen, Deerberg, and
Wcislo [28] described a spontaneous mutation in the
Sprague-Dawley strain of rats, the Han:SPRD, that in-
herited PKD as an autosomal-dominant trait [28]. The
PKD in this rat has been extensively characterized [14].
Heterozygous animals develop slowly progressive renal
cystic disease, whereas homozygotes develop massive cys-
tic enlargement leading to death from uremia at about
4 weeks of age. This rat model exhibits many of the
features of ADPKD in humans, including autosomal-
dominant inheritance, progression to end-stage renal fail-
ure with uremia, hypertension and anemia, and bilateral
renal involvement with cysts that derive from all tubular
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Fig. 13. Short-term caspase inhibition study. The pan caspase inhibitor
IDN-8050 (1 mg) or vehicle [polyethylene glycol 300 (PEG 300)] was
administered intraperitoneally in homozygous (Cy/Cy) rats. Caspase-3
and caspase-7 activity was measured in the Cy/Cy kidneys 3 hours after
the administration of the inhibitor. Caspase activity in the kidney was
massively reduced in IDN-8050 compared to vehicle-treated rats. ∗P <
0.05 vs. vehicle-treated (N = 6) and IDN-8050 group (N = 3).
segments. We have previously described the presence of
increased apoptosis and caspase activity in cystic kidneys
of Han:SPRD rats [9]. In the present study, we used this
model to further study the molecular pathways of caspase
activity and apoptosis in ADPKD.
While apoptosis is a pathologic feature of animal mod-
els of PKD [1–4], experimental models of PKD [6–8] and
kidneys of humans with ADPKD [3], there have been few
studies of the molecular pathways of this apoptosis. In
cell culture, the balance between pro- and antiapoptotic
Bcl-2 family proteins has been found to control caspase-3
activity by regulating cytochrome c release via the mito-
chondrial pathway of apoptosis [23, 29]. In support of a
role of the mitochondrial pathway of apoptosis in PKD
is the demonstration that Bcl-2–deficient mice have in-
creased apoptosis and die from severe polycystic kid-
ney disease [8, 30, 31]. Also, in human kidneys with
ADPKD, levels of antiapoptotic Bcl-2 mRNA and pro-
tein are markedly elevated [2]. However, in the SBM
transgenic mouse model of PKD, both apoptosis and pro-
liferation are c-myc driven and are independent of Bcl-2,
p53, and Fasl/Fas interaction [32, 33]. Increased caspase-3
activity and caspase-7 mRNA has been detected in cys-
tic kidneys in congenital polycystic kidney (cpk) mice, a
model of ARPKD [18]. In the former study, caspase-4
activity which is known to activate caspase-3 via the ex-
trinsic pathway of apoptosis [34] was also increased. In
the present study in ADPKD, we further investigated the
individual caspases that are components of the extrinsic
and intrinsic apoptosis pathways.
The caspases are a family of intracellular cytoplas-
mic cysteine proteases. Caspases share a predilection for
cleavage of their substrates after an aspartate residue
[35]. There are 14 members of the caspase family, cas-
pases 1 to 14. The members of the caspase family can
be divided into subfamilies based on substrate specificity
and function [19]. Caspase-1 [previously known as IL-1
converting enzyme (ICE)] plays a major role in the ac-
tivation of proinflammatory cytokines and not in apop-
tosis. We have demonstated that caspase-1 is a mediator
of ischemic acute renal failure in mice [36, 37]. No in-
crease in proinflammatory caspase-1, however, was seen
in 3-week-old Han:SPRD rat kidneys.
Caspase-3 plays a crucial and extensively studied role
in the promotion of apoptotic cell death [11]. Activation
of caspase-3 results in severing of contacts with surround-
ing cells, reorganization of the cytoskeleton, inhibition of
DNA replication, disruption of the nuclear structure, and
disintegration of the cell into apoptotic bodies. Increased
caspase-3 activity may be due to increased expression of
mRNA and/or protein [38]. In the present study, mRNA
for procaspase-3 was no different in +/+, Cy/+, and
Cy/Cy rats. On immunoblot for caspase-3, there was an
increase in the 32 kD proform. The increase in protein
without an increase in mRNA suggests that regulation
of the protein is post transcriptional and could involve
translational control or changes in protein turnover. In
this regard, the posttranscriptional regulation of caspase-
3 protein was recently described during skeletal muscle
development [39].
Caspase-7, like caspase-3, is an “executioner” cas-
pase and is downstream of the “initiators” caspase-8
and caspase-9 (Fig. 1). Both the intrinsic and extrin-
sic pathways activate caspase-7 (Fig. 1). Caspase-3 and
caspase-7 exhibit very similar substrate specificities in
peptide hydrolysis assays in vitro [40]. However, the
role of caspase-7 during the execution phase of apop-
tosis is obscure [41]. Caspase-7 is unable to cleave the
well-known caspase-3 substrates, including fodrin, gel-
solin, DNA fragmentation factor 45 (DFF45), inhibitor
of apoptosis proteins (IAP), and signal transducer and
activator of transcription-1 (STAT-1) [41]. Also, caspase-
7 is unable to activate caspases that would normally be
activated by caspase-3 [42]. It is known that caspase-3
and caspase-7 can act independently as “executioners”
of apoptosis [43]. Both caspase-3 and caspase-7–deficient
mice are perinatally lethal due to a lack of apoptosis [44].
Caspase-7 may play a more specialized role in apoptosis
than caspase-3 [41]. In the present study, there was an in-
crease in both caspase-3 and caspase-7 protein suggesting
that both these caspases may be involved in ADPKD. The
precise determination of which “executioner” caspase is
the mediator of ADPKD would require inhibitors that
are specific for individual caspases. While the therapeutic
efficacy of pan caspase inhibitors has been demonstrated
in animal models of disease, in vivo inhibitors of specific
caspases have not yet been widely studied.
Next, pathways of caspase-3 and caspase-7–mediated
apoptosis were investigated in the kidneys of 3-week-old
Han:SPRD rats. The “initiator” caspase-8 and caspase-9
are major players in the “extrinsic” and “intrinsic” path-
ways of apoptosis, respectively. Caspase-8 and caspase-9
activate the “executioner” caspase-3 and caspase-7. The
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critical role of the “initiator” caspase-9 is illustrated in
caspase-9 knockout mice that demonstrate the absence
of downstream caspase-3 activation [45]. In the present
study, there was an increase in both caspase-8 (extrinsic
pathway) and caspase-9 (intrinsic pathway) protein. Fur-
ther investigation demonstrated cytochrome c release, an
essential event in the mitochondrial pathway. It is known
that there may be an interconnection between the intrin-
sic and extrinsic pathways via cleavage of the proapop-
totic protein, BID, by caspase-8 [46].
Caspase-2 is a recently discovered caspase that is a crit-
ical initiator of the mitochondrial apoptosis pathway [13].
Activation and increased activity of caspase-2 is required
for the permeabilization of mitochondria and release of
cytochrome c [13]. Caspase-2 activity was increased in
Cy/Cy rat kidneys. However, mRNA for procaspase-2
was no different in +/+, Cy/+, and Cy/Cy rat kidneys
suggesting that the increased caspase-2 activity may be
due to regulation of the protein at a translational level or
increased stability of the caspase-2 protein.
The death receptors (CD95/Fas/APO-1, TNFR1, DR3/
WSL-1/TRAMP, DR4/TRAIL-R1, DR5/TRAIL-R2,
and DR6) are a subset of the tumor necrosis factor (TNF)
receptor family of cell surface molecules that possess a
common motif within their cytoplasmic tails, called the
death domain. The death domains of these receptors re-
cruit adapter molecules that, in turn, recruit caspases to
the receptor complex. In the extrinsic pathway the death
receptors use adapter molecules that recruit caspase-8
[47]. There was no increase in FasL mRNA, an important
death receptor ligand in the extrinsic pathway. In normal
kidney tubular epithelium, tubules stimulated with in-
flammatory mediators and in glomerular injury, FasL pro-
tein was regulated in concert with mRNA abundance [48].
These data suggest that the extrinsic pathway in ADPKD
is independent of the death receptor ligand, FasL.
In the 3-week-old Cy+ rats, the increase in cyst forma-
tion precedes the increase in caspase activity. These data
suggest that the caspase pathways may not be playing an
important role in initial cystogenesis in the Cy/+ rats. In
the 8-week-old Cy/+ rats, the increase in caspase activity
precedes the increase in serum creatinine. The possible
mechanisms by which caspases and apoptosis may con-
tribute to renal failure in polycystic kidney disease are
not well understood. An increase in caspase activity and
apoptosis localized primarily in the interstitium with lit-
tle evidence of cell death in cyst epithelium or noncystic
tubules has been described in the cpk mouse model of
ARPKD [18]. Thus, caspases and apoptosis may destroy
the renal interstitium, thereby allowing cystic epithelium
to proliferate [49]. In the Cy/Cy rats, the cystic epithelium
“survives” as opposed to the non cystic epithelium that
virtually vanishes. We have previously described the pres-
ence of apoptosis in noncystic tubules [9]. In 6-week-old
Cy/+ Han:SPRD rats, 41% of the terminal deoxytrans-
ferase (dTd) uridine triphosphate (UTP) nick-end label-
ing (TUNEL)-positive cells were in noncystic tubules [9].
Thus, it is possible that caspase-mediated apoptosis may
lead to the loss of noncystic tubules and renal failure
in PKD. However, in the present study, active caspase-
3 staining was not seen in 3-week-old +/+ and Cy/+ rat
kidneys but was demonstrated in both tubular cells lining
cysts and in the interstitium in Cy/Cy rat kidneys. Iden-
tification of the cellular pathways involved in apoptosis
and the localization of increased caspase activity in the
kidney may provide insight into the pathogenesis of cyst
formation and renal failure as well as potential therapies
in ADPKD.
Pancaspase inhibitors have been used in vivo in animal
studies to treat a wide variety of acute disease processes
[50]. The therapeutic potential of caspase inhibitors in
ADPKD has not been explored. It is not known whether
intraperitoneal administration of a caspase inhibitor re-
sults in inhibition of caspase activity in the massively
enlarged polycystic kidney. Thus, short-term treatment
of Cy/Cy rats with a caspase inhibitor was investigated.
Intraperitoneal administration of the caspase inhibitor
IDN-8050 in the short-term virtually completely inhibits
caspase-3 and caspase-7 activity in Cy/Cy kidneys. The
effect of long-term administration of these pancaspase
inhibitors on apoptosis in cystic and non cystic epithe-
lium and the interstitium as well as cyst formation and
mortality in Cy/Cy rats is worthy of study.
CONCLUSION
In 3-week-old Cy/Cy Han:SPRD rat kidneys there is
(1) increased activity and protein of the “executioner”
caspase-3 and caspase-7, (2) increased activity and pro-
tein of the “initiator” caspase-9 that coincides with an
increase in cytochrome c (15 kD) release into the cytosol
and an increase in caspase-2 activity demonstrating in-
volvement of the intrinsic pathway, and (3) increased ac-
tivity and protein of the “initiator” caspase-8 suggesting
involvement of the extrinsic pathway. In addition, there
was no increase in FasL mRNA, suggesting that the ex-
trinsic pathway is independent of the death receptor lig-
and, FasL.
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